Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

OBJECTIVES: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient’s well-being during treatment with nab-paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. PARTICIPANTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiorean, E Gabriela, Von Hoff, Daniel, Wan, Yin, Margunato-Debay, Sandra, Botteman, Marc, Goldstein, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987855/
https://www.ncbi.nlm.nih.gov/pubmed/29910636
http://dx.doi.org/10.2147/CMAR.S163475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987855/
https://www.ncbi.nlm.nih.gov/pubmed/29910636
http://dx.doi.org/10.2147/CMAR.S163475

Ejemplares similares